HC Wainwright Forecasts Surrozen FY2026 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Analysts at HC Wainwright issued their FY2026 EPS estimates for Surrozen in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($12.01) for the year. HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2026 earnings at ($1.40) EPS, FY2027 earnings at ($5.19) EPS, FY2028 earnings at ($5.46) EPS, FY2029 earnings at ($5.64) EPS and FY2030 earnings at ($5.35) EPS.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Monday, November 9th. The company reported ($11.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($9.92).

A number of other equities research analysts have also issued reports on SRZN. Guggenheim set a $80.00 target price on shares of Surrozen and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald lifted their price target on Surrozen from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday. William Blair started coverage on Surrozen in a report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Zacks Research upgraded Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Surrozen has an average rating of “Moderate Buy” and a consensus target price of $61.75.

Surrozen Price Performance

Shares of SRZN stock opened at $31.88 on Thursday. The firm has a fifty day moving average of $25.54 and a two-hundred day moving average of $25.42. The firm has a market cap of $370.13 million, a P/E ratio of -0.74 and a beta of 0.51. Surrozen has a 1-year low of $12.12 and a 1-year high of $37.83.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC acquired a new position in Surrozen in the third quarter valued at approximately $45,000. China Universal Asset Management Co. Ltd. raised its position in shares of Surrozen by 37.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company’s stock worth $160,000 after purchasing an additional 1,350 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Surrozen in the 2nd quarter worth approximately $399,000. Perceptive Advisors LLC bought a new stake in shares of Surrozen in the 1st quarter worth approximately $6,682,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Surrozen in the 1st quarter worth approximately $350,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.